Ibrutinib capsules are a medication used to treat mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. The recommended dose of ibrutinib capsules is once daily, at approximately the same time each day. Swallow the capsules whole with water. Do not open, break or chew the capsules.
This is the Chinese package insert for Ibrutinib Capsules (商品名称 亿珂®/IMBRUVICA®), a 140 mg hard gelatin capsule from Xi'an-Janssen. It states that the capsules, taken orally once daily, are indicated as monotherapy for patients with mantle cell lymphoma (MCL) and for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior therapy.
The insert details the recommended doses (560 mg once daily for MCL; 420 mg once daily for CLL/SLL), dose adjustments for toxicity, co-administration with CYP3A inhibitors, use in hepatic impairment, missed doses, and special populations such as women and men of childbearing potential. It then presents adverse reaction data from clinical trials including PCYC-1104-CA, MCL-3001, PCYC-1102-CA, PCYC-1112-CA, PCYC-1115-CA and CLL-3001. This manual is written in Chinese.
| Active ingredient | Ibrutinib (伊布替尼) |
|---|---|
| Strength | 140 mg |
| Molecular formula | C25H24N6O2 |
| Molecular weight | 440.50 |
| Capsule appearance | Size 0 white opaque hard gelatin capsule printed in black ink with "ibr 140mg"; contents are white or almost white powder |
| Excipients | Microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, gelatin empty capsule |
| Recommended dose for MCL | 560 mg (4 capsules of 140 mg) once daily until disease progression or unacceptable toxicity |
| Recommended dose for CLL/SLL | 420 mg (3 capsules of 140 mg) once daily until disease progression or unacceptable toxicity |
It is used as monotherapy for patients with mantle cell lymphoma who have received at least one prior therapy, and for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one prior therapy.
The capsules are given orally once daily, swallowed whole with water at roughly the same time each day; do not open, break or chew the capsule.
If a dose is not taken at the planned time, it can be taken as soon as possible the same day, and the normal schedule resumes the next day; do not take an extra dose to make up for the missed one.
The recommended dose for MCL is 560 mg (four 140 mg capsules) once daily until disease progression or unacceptable toxicity.